Premium
Is the era of prostate‐specific antigen over?
Author(s) -
Djavan Bob,
Rocco Bernardo,
Stangelberger Anton,
De Cobelli Ottavio,
Marberger Michael
Publication year - 2007
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2007.06944.x
Subject(s) - medicine , prostate specific antigen , prostate , antigen , prostate disease , prostatic disease , immunology , cancer
In a controversial analysis, histological variables from 1317 radical prostatectomy specimens were examined and categorized in 5-year periods of resection from 1983 to 2003 [9]. For the first 5-year period, serum PSA level was a significant predictor of the volume of the largest tumour, capsular penetration, lymph-node positivity, seminal vesicle invasion, likelihood of the largest tumour having a Gleason score of 4 or 5, and prostate weight. However, for the last 5-year period, PSA was only a significant predictor of the volume of the largest tumour and prostate weight. Do these findings indicate, as proposed by Stamey et al. [9] that ‘the PSA era is probably over for prostate cancer’? In another study, which examined 2312 radical prostatectomy specimens resected between 1992 and 2004 by one surgeon, the PSA level was significantly correlated with biochemical progression [10], whereas a further analysis of 2977 specimens, mostly from a screening study, showed that PSA level was more strongly correlated with the percentage of cancer and cancer volume than with prostate size [11].